80 results about "Tubular cell" patented technology

A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

An anode-supported tubular fuel cell stack includes interconnect structures that are oxidation resistant at high temperature, flexible to accommodate thermal expansion stress and to provide strong electrical contact, have low electrical resistance, and are inexpensive and light weight. The interconnect structures may be formed out of metal sheet, which provide improved heat homogeneity throughout the fuel cell stack because of the high thermal conductivity of the metal. The interconnect structures are further shaped to provide resilience or spring-like features to allow movement between the tubular cells. Thus good electrical contact, thermal stress release, and shock absorption are simultaneously achieved.

A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

A rig mat is formed by rectangular panels fastened end to end by cooperating connectors. In one arrangement the first connector is C-shaped shaped to form a slot and the second T-shaped shaped with a flange of the T wider than the mouth inserted through the mouth. In a second arrangement two L shaped connectors are interengaged with an additional flat plate which defines a slot with an end of one of the L-shaped connectors. The panels are composite and formed from a honeycomb core panel with a foam material filling the tubular cells and a fibrous reinforcing cover sheets extending over the top and bottom of the panel. The cover sheets are filled with a set resin material which extends into the porous fibrous material of the walls of the core panel so as to form an integral structure of the resin extending between the walls and the sheets.

An early-onset method and kit for detecting renal tubular cell injury, using NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and thus readily detected in urine following tubular cell injury. NGAL protein expression was mainly detected in the proximal tubule cells, which resembled a secreted protein with a punctate distribution in the cytoplasm. Apparent NGAL in urine correlates with the amount and duration of renal ischemia and nephrotoxicemia and is a diagnostic feature of tubular cell injury and renal failure. NGAL detection is also a useful marker for monitoring nephrotoxic side effects of drugs or other therapeutic agents.

Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time is disclosed. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and / or maintaining a proper treatment regimen to slow or stop the progression of CRF.

A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

A method of immunomodulation by contacting the bodily fluid of a patient with renal tubule cells outside of the kidney.

A front door 20 includes a first door component 22 and a second door component 34. The first door component 22 forms an inner side portion of a door main body 21, and the second door component forms an inner side portion of the door main body 21 and has functional parts located inside the vehicle. The first and second door components 22, 34 have honeycomb structural bodies 23, 41, respectively. The honeycomb structural bodies 23, 41 are entirely formed of synthetic resin. The honeycomb structural bodies 23, 41 include honeycomb portions 24, 42, which are composed of numerous tubular cells 26, 44, 45 separated by partition walls 25, 43, and sealing plate portions 27, 28, 46, 47 that are located on the outer side and the inner side of the honeycomb portions 24, 42 and seal the cells 26, 44. The door components 22, 34 are joined to each other at least at a part of the adjacent sealing plate portions 28, 46 of the honeycomb structural bodies 23, 41.

A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

The invention discloses a low-intensity pulse ultrasound-assisted rotary tubular cell / tissue culture system. The Lipus-assisted rotary tubular cell / tissue culture system comprises a culture main body provided with a rotating shaft, wherein an air chamber is sheathed outside the culture main body, the rotating shaft is arranged at both ends of the air chamber, one end of the culture main body is provided with an Lipus ultrasound instrument, the ultrasound transmitting probe of the Lipus ultrasound instrument is inserted into the culture main body, and the inner wall of the air chamber is provided with an oxygen concentration controlling part. The culture system can realize on-line oxygen supply and liquid supply, thereby being beneficial to the transport of oxygen, carbon dioxide and metabolin in the system and being capable of accurately controlling the oxygen concentration. By using the Lipus ultrasound instrument as an auxiliary means, the invention creates a favorable microenvironment for the proliferation or differentiation of cells or tissues, ultimately simulates the micro-gravity environment for carrying out three-dimensional dynamic culture, and can realize functions of oriented amplification and induced differentiation.

The present invention concerns bioactive renal cell populations, in particular a B2 cell population comprising an enriched population of tubular cells and wherein the renal cell population is depleted of a B1 cell population, renal cell constructs, and methods of screening test agents using the bioactive renal cell populations.

A tubular fuel cell module is provided with a tubular cell of a tubular fuel cell, and a heat transfer pipe through which a heating / cooling medium flows to selectively heat and cool the tubular fuel cell. The heat transfer pipe includes a first straight portion, a second straight portion, and a bent portion that connects the first straight portion with the second straight portion. At least a portion of the tubular cell is arranged on at least one of the first straight portion and the second straight portion. As a result, the reliability of a seal of the tubular fuel cell module is improved.

Composite joint for fitting at least one external member to a sandwich panel and panel integrating at least one such joint. To permit the transmission of static and / or dynamic stresses between at least one external member and a sandwich panel, into said panel is integrated at least one composite joint (10). Said joint comprises a plurality of juxtaposed, elementary, tubular cells (12), oriented in the panel thickness direction, as well as at least one stress introduction cell (12a), in which is fitted a rigid part (14) for fixing the external member. The tubular cells (12) comprise composite walls formed from braided fiber roves and resin.

Composite joint for fitting at least one external member to a sandwich panel and panel integrating at least one such joint.To permit the transmission of static and / or dynamic stresses between at least one external member and a sandwich panel, into said panel is integrated at least one composite joint (10). Said joint comprises a plurality of juxtaposed, elementary, tubular cells (12), oriented in the panel thickness direction, as well as at least one stress introduction cell (12a), in which is fitted a rigid part (14) for fixing the external member. The tubular cells (12) comprise composite walls formed from braided fiber roves and resin.

There is provided an in vitro assay for screening a test compound for toxicity in renal proximal tubular cells. The method comprises contacting a test compound with a test population of renal proximal tubular cells; and determining the expression level of an interleukin in the test population, the interleukin being interleukin-6 (IL-6) or interleukin-8 (IL-8), or both. Expression levels of the interleukin in the test population being greater than expression levels in a control population of renal proximal tubular cells not contacted with the test compound is indicative that the test compound is toxic for renal proximal tubular cells.

The present invention concerns bioactive renal cell populations, in particular a B2 cell population comprising an enriched population of tubular cells and wherein the renal cell population is depleed of a B1 cell population, renal cell constructs, and methods of screening test agents using the bioactive renal cell populations.

The invention discloses a preparation method of a quality control material / control substance for a urine visible component analyzer. The preparation method comprises the following steps: preparation of an erythrocyte simulant, preparation of a leukocyte simulant, preparation of a tubular cell simulant and preparation of the quality control material; independent or random combination of the several simulants to synthesize the required quality control material / control substance, wherein the obtained quality control material / control substance can be applied to the urine visible component analyzer or a hematology analyzer. According to the preparation method, by cell treatment and improvement on a treatment liquid formula, the prepared quality control material / control substance can make up for the shortcoming of lack of quality control materials in China.

A self-reinforced masonry block comprises a main body having opposed substantially parallel stacking surfaces and at least one tubular cell defined therethrough from one stacking surface to the other. At least one confining reinforcement is embedded in the main body to surrounding a corresponding cell. Each confining reinforcement extends substantially entirely along the longitudinal length of its corresponding cell and terminates inwardly of the stacking surfaces. The self-reinforced masonry blocks may be used in construction of a grout-filled, vertically reinforced masonry block wall, with the self-reinforced masonry blocks being used for those portions of the wall where the grouted cells are prone to crushing due to high levels of compressive stress, and conventional unreinforced masonry blocks being used for other portions of the wall. A method for making the self-reinforced masonry blocks is also described.

The invention relates to the technical field of traditional Chinese medicines, in particular to a medicine for treating renal fibrosis and a preparation method thereof. The 31 traditional Chinese medicinal materials provided by the invention have the effects of anti-renal fibrosis, anti-heart-kidney syndrome, anti-heart failure, anti-nephrotic syndrome and / or anti-renal failure medicines; a composition prepared from rhizoma atractylodis macrocephalae, puffball, lysionotus pauciflorus and periostracum cicadae can inhibit renal tubular cell epithelial-mesenchymal transition and inhibit the transcription level of key genes, and therefore renal fibrosis, heart-kidney syndrome, heart failure, nephrotic syndrome and renal failure can be effectively treated.

A spacer grid specifically designed for accident tolerant fuel utilizing fuel rods with SiC cladding for implementation in pressurized water reactors. The spacer grid tubular generally square design allows for ease of SiC fuel rod insertion during the fuel assembly fabrication process by providing a smooth contact geometry. The co-planar vertically oriented support allows the fuel rods to be rotated axially more freely at the grid location than a conventional six-point contact geometry used in existing fuel assembly designs. Since the SiC fuel rod has higher stiffness than a metallic fuel rod, the six-point contact geometry, which consists of two spring and four dimples, can potentially damage the fuel rod in the event of fuel rod deflection induced by a seismic event or a bowed fuel assembly. The fuel rod support cells are attached at their corners which are shared between adjacent support cells.

The invention discloses application of melbine in preparing medicines for relieving cisplatin-induced acute kidney injury related diseases, and discloses application of melbine in new indication. The melbine disclosed by the invention can be used for relieving cisplatin-induced acute kidney injury related diseases which include acute kidney injury renal function, apoptosis of renal tubular cell, renal inflammatory cell infiltration and like diseases; and acute kidney injury is relieved by inhibiting the apoptosis of renal tubular cell mainly by improving the autophagy level of the renal tubular cell.

There is provided a method of making a renal tubule. The method comprises seeding renal tubule cells onto a solid surface; culturing the renal tubule cells in a liquid growth medium to form a monolayer on the solid surface; and continuing culturing the renal tubule cells to form a tubule.

The invention provides an application of inhibitor of histone deacetylase HDAC 6 in preparing drugs for preventing and treating acute kidney injury. Furthermore, the histone deacetylase HDAC 6 is Tubastatin A. The selective inhibitor of HDAC 6 can lighten the renal pathology damage of acute kidney injury induced by cis-platinum and improve the kidney function. The HDAC6 inhibitor TA can lower the release of inflammatory factors and lighten the oxidative stress reaction through regulating an AKT signal access, an NF-KB inflammation access, an autophagy level and an E-cadherin expression; thus the apoptosis of kidney tubule cell and necrosis of tubule expansion are reduced, the renal pathology damage and kidney function are improved; the inhibitor can protect the kidney structure and function in the acute kidney injury. Therefore, HDAC6 is likely to be an important target point to prevent and treat the acute kidney injury.

The invention specifically relates to application of bupleurum polysaccharide in preparation of drugs used for preventing and treating diabetic nephropathy, which belongs to the field of traditional Chinese medicine. According to results of integral experiments and in-vitro experiments, bupleurum polysaccharide extract has obvious prevention and treatment effect on diabetic nephropathy. Bupleurum polysaccharide can improve the body weight of diseased animals, substantially reduce the level of blood sugar and urine sugar, obviously promote secretion of insulin, decrease the level of serum creatinine, reduce secretion level of microalbuminuria and the renal index and enhance renal pathological symptoms, thereby exerting blood sugar-reducing and kidney-protecting effect. Bupleurum polysaccharide can reverse tubular cell transdifferentiation causec by TGF-beta. The bupleurum polysaccharide can be used for preparation of drugs used for preventing and treating diabetes and renal complications caused by diabetes.

The invention provides application of Src kinase inhibitor in preparing medicaments for treating acute kidney injury. Further, the acute kidney injury is caused by renal ischemia. Further, the Src kinase inhibitor is PP1 (4-Amino-5-(methylphenyl)-7-(t-butyl)pyrazolo-(3,4-d)pyrimidine). The invention proves that PP1 inhibition of Src can relieve the pathobiological change of kidney after I / R, so as to improve kidney function. The treatment mechanism of the Src kinase inhibitor includes procedures of inhibiting apoptosis of renal tubule cells, protecting multiple connexins and adhesive proteins, and inhibiting cell death and inflammation signal pathway.

The invention provides application of trehalose in preparation of a medicine for relieving renal ischemia-reperfusion injury, and belongs to the field of biological medicines. The application proves that trehalose can alleviate ischemia-reperfusion induced acute kidney injury related diseases, including acute kidney injury renal function, oxidative stress, renal tubular cell apoptosis, renal inflammatory cell infiltration and the like, by enhancing autophagy, thereby providing a theoretical basis for widening the possible application range of trehalose. As trehalose has been approved to be a safe food component by American Food and Drug Administration at present and has been applied to food preservation and other work, it is found that effective clinical drugs are extremely likely to be provided for prevention and treatment of AKI.

There is provided a method of differentiating an induced pluripotent stem cell (iPSC) into a renal proximal tubular cell (PTC)-like cell. The method comprises culturing an undifferentiated iPSC in a renal epithelial cell culture medium in the presence of one or more extracellular matrix (ECM) molecules, bone morphogenic protein 2 (BMP2) and bone morphogenic protein 7 (BMP7), for a period of from about 8 to about 10 days, under conditions sufficient to induce differentiation of the iPSC into a PTC-like cell. A cell population of differentiated PTC-like cells is also provided, as well as uses and methods of use of the cell population.